Bayer's Legislative Strategy to Counter Litigation Onslaught

Bayer AG pushes legislation in multiple US states to protect pesticide makers from liability claims, as it forecasts stable 2026 profits despite ongoing Roundup litigation and pharma competition.

Facing a persistent wave of lawsuits related to its Roundup weedkiller, Bayer AG is pursuing a coordinated legislative strategy across the United States. The company is actively supporting draft legislation in approximately a dozen U.S. states designed to shield pesticide manufacturers from specific liability claims.

A Multi-State Legal Defense Initiative

This approach represents a new front in Bayer's long-running battle against litigation. The company's efforts are focused on bills that would protect producers from lawsuits alleging inadequate warning labels about potential health risks, including cancer. A recent legislative push occurred in Kansas, where a relevant bill was up for a vote on March 10.

The core of the legal challenge stems from the acquisition of Monsanto, which brought Roundup into Bayer's portfolio. For years, tens of thousands of claims have weighed heavily on the company, creating significant financial uncertainty and influencing its long-term planning.

Financial Outlook Amidst Dual Pressures

Despite this ongoing legal headwind, Bayer issued a financial forecast for 2026 in early March, projecting largely stable profitability. This outlook, however, explicitly accounts for the continued financial burden of U.S. litigation. The company is also navigating pressure within its pharmaceuticals division, where competition from generic drugmakers is impacting certain products.

The market has reflected these combined challenges. Over the preceding 30-day period, Bayer's share price declined by approximately 15 percent, trading notably below its 50-day moving average.

The effectiveness of Bayer's state-level legislative offensive in meaningfully reducing legal uncertainty will become clearer as initial states begin voting on the proposed bills. The outcome could have significant implications for the company's future financial trajectory.